5-year follow up of short-course abiraterone and adt for high-risk prostate cancer
Published 2 months ago • 96 plays • Length 1:38Download video MP4
Download video MP3
Similar videos
-
1:17
abiraterone for the treatment of cn1 prostate cancer
-
11:22
neoadjuvant androgen deprivation therapy in men with high-risk localized prostate cancer
-
5:07
neoadjuvant abiraterone acetate plus leuprolide acetate in localised high-risk prostate cancer
-
2:04
a phase ii trial investigating neoadjuvant abiraterone and cabazitaxel in high-risk prostate cancer
-
2:44
the role of radiation in managing high-risk localized prostate cancer
-
5:16
exciting advances in systemic therapy for prostate cancer: docetaxel and abiraterone
-
7:29
halving duration of adt for high risk prostate cancer patients
-
2:40
study finds early mental health support for men diagnosed with prostate cancer
-
4:18
abiraterone with or without enzalutamide plus adt for non-metastatic prostate cancer
-
6:25
practice-changing data from esmo 2021 in prostate cancer
-
3:43
startar: adt apalutamide rt docetaxel for psa-recurrent prostate cancer following rp
-
2:45
trial of lhrha, abiraterone and enzalutamide: filling an unmet need in prostate cancer therapy
-
2:14
salv-enza: srt plus enzalutamide for psa recurrent high-risk prostate cancer delays psa progression
-
5:38
case study #1: applying a clinical genomic nomogram to the adt decision in high volume gleason 3 4=7
-
1:30
ai biomarker predicts benefit of long-term adt in prostate cancer
-
3:38
results from peace-1: abiraterone in mcspc
-
22:36
key developments in non-metastatic & metastatic hormone-sensitive prostate cancer
-
2:06
dr. chi on androgen deprivation therapy for high-risk metastatic hormone-naive prostate cancer